Conferences
ASCO GU 2019: Alterations in DNA Damage Repair Genes and Outcomes to Systemic Therapy in IO versus TKI Treated Metastatic Clear Cell Renal Cell Carcinoma Patients
February 17, 2019
ASCO GU 2019: Transitional Surrogate Endpoint for Survival in Phase II Trials for mCRPC - Assessment of Circulating Tumor Cell Number
February 17, 2019
ASCO GU 2019: TALAPRO-2: A Two-Part, Placebo-Controlled Phase III Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
February 17, 2019
ASCO GU 2019: Penile Squamous Cell Carcinoma is Genomically Similar to Other HPV-Driven Tumors
February 17, 2019
ASCO GU 2019: Point-Counterpoint: Subgroup Analyses Can Be Used to Change Clinical Practice Guidelines
February 17, 2019
ASCO GU 2019: The P-Value Debate: Lower Them or Leave Them?
February 17, 2019
ASCO GU 2019: Practice Makes Perfect: Should All Testicular Cancer Cases Be Discussed with High-Volume Centers?
February 17, 2019
ASCO GU 2019: Penile Carcinoma Regional Lymph Node Involvement: Radiation Versus Surgery – Radiation Oncology Perspective
February 16, 2019
ASCO GU 2019: MicroRNA 371 As a Biomarker: Is It a Breakthrough?
February 16, 2019
ASCO GU 2019: Results of a 50 Patient Single-Centre Phase II Prospective Trial of Lutetium-177 PSMA-617 Theranostics in mCRPC
February 16, 2019
ASCO GU 2019: Oligometastatic Disease: Tumor Board - Medical Oncologist Perspective by Silke Gillessen, MD
February 16, 2019
ASCO GU 2019: Oligometastatic Disease: Tumor Board - A Radiation Oncologist Perspective by Gert de Meerleer, MD
February 16, 2019
ASCO GU 2019: Oligometastatic Disease: Tumor Board, A Radiation Oncologist Perspective by Bridget Koontz, MD
February 16, 2019